Syngene International Share Price Live
SYNGENE
Live Syngene International Share Price Chart
Syngene International Performance
Days Range
| Previous Close | ₹399.75 |
|---|---|
| Open | ₹399.2 |
| Volume | 22,60,553 |
| Day's Range | ₹397.85 - ₹412.20 |
|---|---|
| 52W Range | ₹375.25 - ₹684.60 |
| Market Cap | ₹16,286.03 Cr |
Syngene International Fundamentals
| ROCE(TTM) | 9.67 |
|---|---|
| P/E Ratio (TTM) | 73.76 |
| P/B Ratio | 3.36 |
| Industry P/E | 67.46 |
| Debt to Equity | 0.09 |
| ROE | 7.76 |
| EPS (TTM) | 7.34 |
| Dividend Yield | 0.31 |
| Book Value | 119.90 |
| Face Value | 10 |
| ROCE(TTM) | 9.67 |
|---|---|
| P/E Ratio (TTM) | 73.76 |
| P/B Ratio | 3.36 |
| Industry P/E | 67.46 |
| Debt to Equity | 0.09 |
| ROE | 7.76 |
|---|---|
| EPS (TTM) | 7.34 |
| Dividend Yield | 0.31 |
| Book Value | 119.90 |
| Face Value | 10 |
Syngene International Financials
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Net Sales | 910.60 | 917.10 | 1,036.50 | 736.00 |
| Expenses | 827.60 | 821.60 | 844.60 | 757.40 |
| Profit before tax | 85.20 | 28.40 | 196.00 | -19.20 |
| Operating Profit | 67.10 | 15.00 | 147.90 | -9.00 |
| Net Profit | 67.10 | 15.00 | 147.90 | -9.00 |
| EPS in Rs | 1.67 | 2.11 | 3.83 | 0.11 |
Syngene International Shareholding Pattern
Promoters
52.59%
Retail And Others
7.58%
Foreign Institutional Investors
11.82%
Domestic Institutional Investors
28.02%
About Syngene International
Syngene International Ltd is a listed subsidiary of Biocon. It is a contract research, development and manufacturing organisation (CRDMO) which provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies. The company was established in 1993 as Syngene International Private Limited and initiated operations as a Custom Research Organisation (CRO) with services in chemistry and biology in 1994.
In 2002, 99.9% of the company's equity shares were transferred to Biocon as Kiran Mazumdar Shaw, a promoter of Biocon, promoted it. As a result, the company became a subsidiary of Biocon. In 2007, the company signed the first long-term contract with Bristol-Myers Squibb to set up its first dedicated R&D centre.
The company continued its growth trajectory and entered a collaboration with Endo Pharmaceuticals to develop novel biological therapeutic molecules against cancer in 2011. It crossed an annual turnover of over ₹5,000 million in 2013. The company’s erstwhile subsidiary, Clinigene International Limited (CIL), was amalgamated into the company in 2015. During the same year, the company was listed on BSE and NSE after an IPO. The company received the Golden Peacock Award for Risk Management in 2023.
Business Segments
- Discovery Services: Under this segment, the company is responsible for conducting early-stage research, from identifying biological targets relevant to disease in patient populations to delivering drug candidates for further development.
- Development Services: The development services division takes drug candidates and provides various services, from pre-clinical to clinical trials, including drug substance, drug product development, and associated services.
- Manufacturing Services: The company offers commercial-scale manufacturing of small molecules from its cGMP-compliant API manufacturing campus.
- Dedicated R&D Centers: Under this segment, Syngene provides R&D services. The company’s R&D Centers are multi-disciplinary teams based in dedicated facilities focusing on biopharmaceutical research for clients including BMS, Amgen and Baxter.
- Syngene USA Inc. This wholly-owned subsidiary was incorporated in FY 2018 to support Syngene's firm foothold in the US market and allow easy access to its clients based in that region.
- Syngene Scientific Solutions Limited (SSSL): This subsidiary was incorporated in 2022 and is engaged in contract research and clinical research services.
- Syngene Manufacturing Solutions Limited (SMSL): This subsidiary was incorporated in 2022 to manufacture pharmaceutical, biopharmaceutical and biological products of any kind.
Key Personnel
Jonathan Hunt, Managing Director and Chief Executive Officer Jonathan holds is the current MD and CEO of the company. His responsibilities revolve around leading the company’s business and driving its investments in developing and strengthening its capabilities and capacities. He holds a BA (Business Studies & Economics) degree from the University of Sheffield, UK, and has done his MBA from Durham University, United Kingdom. He held leadership positions at AstraZeneca for over a decade before joining Syngene.Corporate Action
In 2019, the company issued bonus shares in the ratio of 1:1 on a record date of June 11, 2019.Parent Organisation
Indian Private
Managing Director
Peter John Bains
Founded
1993
NSE Symbol
SYNGENE
Top Mutual Funds Invested in Syngene International Share
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | 8,945.0 -29.50 (-0.33%) | ₹1,29,125.81 | 6,696.5 - 9,050.0 |
| Max Healthcare Institute Ltd | 1,070.0 -2.40 (-0.22%) | ₹1,04,429.06 | 903.0 - 1,301.7 |
| Manipal Health Enterprises Ltd | 677.95 27.45 (4.22%) | ₹89,103.65 | 625.45 - 691.8 |
| Aster DM Quality Care Ltd | 869.7 25.25 (2.99%) | ₹75,861.65 | 519.1 - 875.35 |
| Fortis Healthcare Ltd | 955.15 35.15 (3.82%) | ₹72,475.98 | 766.8 - 1,104.3 |
| Global Health Ltd | 1,455.6 11.30 (0.78%) | ₹39,120.84 | 956.0 - 1,483.7 |
Popular Stocks
Syngene International Ltd FAQs
What is the share price of Syngene International Ltd (SYNGENE) shares?
Syngene International Ltd (SYNGENE) share price as of August 7, 2026, on NSE is Rs 403.7 (NSE) and Rs 403.7 (BSE) on BSE.
Can I buy Syngene International Ltd (SYNGENE) from Angel One?
Yes, You can buy Syngene International Ltd (SYNGENE) shares by opening a Demat account with Angel One.
How do I buy Syngene International Ltd (SYNGENE) from Angel One?
Syngene International Ltd (SYNGENE) share can be bought through the following modes:
1. Direct investment: You can buy Syngene International Ltd (SYNGENE) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Syngene International Ltd (SYNGENE) shares.
1. Direct investment: You can buy Syngene International Ltd (SYNGENE) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Syngene International Ltd (SYNGENE) shares.
What is the main business of Syngene International?
The main business of Syngene International is to research, develop, and provide scientific molecules and solutions across varied industries, such as pharmaceuticals, animal health, biotechnology, consumer goods, nutrition, and specialty chemical companies.
Who are the promoters of Syngene International?
Some of the main promoters of Syngene International are Biocon Limited, Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha), Kiran Mazumdar Shaw, Biocon Research Limited, Ravi Rasendra Mazumdar, and Dev Mazumdar.
What are the Subsidiaries that comes under Syngene International?
The only wholly-owned subsidiary that comes under Syngene International is Syngene USA Inc.
What is the market cap of Syngene International?
The market cap of Syngene International is Rs. 16286.03 Cr. as of 08/08/2026.
What is the current P/E ratio of Syngene International?
The P/E ratios of Syngene International is 73.76 as of 08/08/2026.
What is the current PB ratio of Syngene International?
The PB ratios of Syngene International is 3.36 as of 08/08/2026.
